ReviewFrontiers in psychiatry2026
Quantitative electroencephalography as a potential neurophysiological diagnostic biomarker of schizophrenia and first-episode psychosis: a systematic review of clinical implications.
Review in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Hypothesis: Schizophrenia affects approximately 1% of the global population, with early diagnosis critical for optimal treatment outcomes. Resting-state quantitative electroencephalography (qEEG) represents a promising, non-invasive biomarker. We hypothesized that 18 years after the seminal Boutros review, advances in qEEG methodology would demonstrate characteristic neurophysiological signatures distinguishing schizophrenia from healthy controls and first-episode psychosis. Study Design: This systematic review followed PRISMA guidelines, searching PubMed, Google Scholar, and Scopus for studies published after 2008. Inclusion criteria required adult human studies comparing resting-state qEEG in patients with schizophrenia or first-episode psychosis versus healthy controls. Studies employing advanced artificial intelligence techniques, evoked potentials, and task-based recordings were excluded to focus on classical qEEG parameters applicable in clinical settings from 467 publications after temporal restriction, 19 original studies met inclusion criteria. Across the studies included in this review, a total of 1242 patients were analyzed, comprising 981 individuals diagnosed with schizophrenia and 261 individuals with a first episode of psychosis. These cohorts were compared with 1211 healthy control participants across studies. Study Results: Chronic schizophrenia patients consistently demonstrated increased delta and theta wave activity in anterior regions and decreased alpha peak frequency in posterior areas. These alterations were less pronounced or absent in first-episode psychosis, suggesting progression with disease duration or long-term treatment. The novel theta/alpha component (6-9 Hz) identified by Nakhnikian et al. provides mechanistic insight into alpha slowing. Significant methodological heterogeneity precluded meta-analysis. Conclusions: Characteristic qEEG alterations exist in chronic schizophrenia but remain inconsistent in early psychosis. The unique theta/alpha signature represents a promising specific biomarker. However, persistent methodological heterogeneity limits clinical translation. Standardized multicenter protocols with longitudinal designs are essential before qEEG implementation in routine schizophrenia diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.